Immunophenotyping analyses already suggested that these drugs could eliminate bulk blast cells without eradicating leukaemia stem and progenitor cells in AML patients42 and did not correct CD34+ cell immunophenotypic aberrancies in CMML patients43. This evidence concerns the gene CD34 and leukemia.